Drug intelligence / Profile preview

LN016 (bupivacaine)

Development stage
Phase 2
Lead developer
Shanghai Huiyong Pharmaceutical
Modality
Small Molecules, Hydrogel Systems → Drug Delivery Systems
Administration
Topical
01

Overview

LN016 is a sustained-release gel formulation of the local anesthetic bupivacaine (specifically bupivacaine hydrochloride) developed by Shanghai Huiyong Pharmaceutical. It is designed for local instillation into surgical wounds to provide prolonged postoperative analgesia. By utilizing a sustained-release gel delivery system (incorporating the novel excipient EN001), LN016 slowly releases bupivacaine at the surgical site, blocking voltage-gated sodium channels on local nerve fibers to prevent the generation and conduction of pain signals. It is currently in Phase 2 clinical development in China for postoperative pain management following surgeries such as inguinal hernia repair and abdominal procedures.

Other names
bupivacaine hydrochlorideLN016 sustained-release gelLN-016 sustained-release gelLN 016 sustained-release gel
02

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)Kir (Inward-rectifier potassium channels)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on LN016 (bupivacaine).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LN016 (bupivacaine).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call